Eimskip Publishes Q2 2025 Results, Sets Investor Meeting on August 27

Eimskip will publish its Q2 2025 results after market closing on Aug 26. Investors and market participants are invited to a meeting on Aug 27 at 8:30 GMT at the company's headquarters. The meeting will be webcasted live in Icelandic on the company's website. Questions can be sent to investors@eimskip.com.

Reykjavik, Iceland — Alvotech (NASDAQ: ALVO) has released its Q2 2025 financial results, showcasing significant growth in sales and research expenditures. The company reported a 200% increase in pharmaceutical sales compared to the same period last year, driven by strong demand for its products in Europe, Canada, and the United States. Additionally, Alvotech's research and development costs decreased, reflecting advancements in its product pipeline and strategic acquisitions.

Key highlights from the Q2 2025 results include:

- Pharmaceutical Sales: Sales increased by 204.7 million USD, up from 65.9 million USD in the same period last year. This growth was primarily driven by increased sales of AVT02 and AVT04 in Europe and the United States.

- Research and Development: Research and development costs decreased by 4.6 million USD to 92.9 million USD, reflecting progress in clinical trials and product launches.

- Revenue Growth: Total revenue for the period increased by 20.4 million USD to 346.9 million USD, driven by strong sales and increased research expenditures.

- Net Income: Net income for the period was 141.7 million USD, up from 153.5 million USD in the same period last year. This increase was primarily driven by higher sales and lower research costs.

- Upcoming Events: Alvotech will host a webcast of its Q2 2025 earnings call on August 27 at 8:30 GMT. The call will be available in Icelandic on the company's website. Questions can be sent to investors@alvotech.com.

Alvotech's Q2 2025 results demonstrate the company's continued growth and strategic focus on expanding its product pipeline and entering new markets. The company's strong performance in the first half of the year sets a positive tone for the remainder of the year.

References:
[1] https://www.globenewswire.com/news-release/2025/08/13/3133008/0/is/Alvotech-birtir-uppgj%C3%B6r-fyrir-fyrstu-sex-m%C3%A1nu%C3%B0i-%C3%A1rsins-og-kynnir-n%C3%BDjustu-%C3%A1fanga-%C3%AD-rekstri-f%C3%A9lagsins.html